Modified exotoxin a proteins
AssigneeGlaxosmithkline Biologicals SA
InventorsStefan Jochen KEMMLER, Christian LIZAK, Gerald Johann POSCH, Julien Laurent QUEBATTE
Life of this patent
Estimating the term…
Abstract
The present invention relates to the field of modified proteins, immunogenic compositions and vaccines comprising the modified proteins, their manufacture and the use of such compositions in medicine. More particularly, it relates to a modified EPA (Exotoxin A of Pseudomonas aeruginosa) protein. The modified EPA can be used as a carrier protein for other antigens, particularly saccharide antigens or other antigens lacking T cell epitopes.
Claims17
1-15. (canceled)
A modified EPA (Exotoxin A of Pseudomonas aeruginosa) protein having an amino acid sequence of SEQ ID NO:
- 1 or an amino acid sequence at least 80%, 85%, 90%, 92%, 95%, 96%, 97%, 98% or 99% identical to SEQ ID NO:
- 1, modified in that the amino acid sequence comprises at least one consensus sequence(s) selected from:
- D/E-X-N-Z-S/T (SEQ ID NO:
- 2) and K-D/E-X-N-Z-S/T-K (SEQ ID NO:
- 3), wherein X and Z are independently any amino acid except proline, wherein the at least one consensus sequences have each been added next to or substituted for one or more amino acids, independently selected from:
- (i) one or more amino acids between amino acid residues 198-218, (ii) one or more amino acids between amino acid residues 264-284, (iii) one or more amino acids between amino acid residues 308-328, and (iv) one or more amino acids between amino acid residues 509-529 of SEQ ID NO:
- 1 or at equivalent position(s) within an amino acid sequence at least 80%, 85%, 90%, 92%, 95%, 96%, 97%, 98% or 99% identical to SEQ ID NO:
- 1.
Dependencies are inferred from the claim text.